Dr. Sheng Chen 陈盛
Chief Physician, Associate Professor
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast cancer radical surgery, breast-conserving surgery, reconstruction, comprehensive care, benign breast tumors, and clinical trials for advanced breast cancer.
Dr. Chen is a Chief Physician, Associate Professor, and Master’s Supervisor at Fudan University Shanghai Cancer Center, serving as Assistant Director of the Department of General Surgery. Dr. Chen performs over 600 breast cancer radical surgeries and 400 benign tumor surgeries annually. Dr. Chen leads three national-level projects and was selected for Shanghai Health Commission young talent programs. In 2020, Dr. Chen was listed among the top 100 influential experts in breast cancer in China.
Professional roles
- Member, Breast Digital Diagnosis and Treatment Professional Committee, China Medical Equipment Association
Name order: in Chinese the family name comes first (Chen Sheng). Papers usually list the name as Sheng Chen or Chen S.
Selected publications
36 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Sci (Weinh), 2026 (senior author): Stress-Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer. PubMed 41486103
- Pharmacol Res, 2024 (senior author): The role of amino acid metabolism alterations in acute ischemic stroke: From mechanism to application. PubMed 39025169
- Front Immunol, 2022 (senior author): SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival. PubMed 36341391
- Breast Cancer Res Treat, 2020 (senior author): Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study. PubMed 32361849
- Int J Cancer, 2017 (first author): PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. PubMed 27925176
- Oncotarget, 2015 (first author): Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. PubMed 26053183
- Clin Cancer Res, 2013 (first author): The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. PubMed 24141623
- Ann Surg Oncol, 2012 (first author): Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. PubMed 22437200
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion